BioMarin Pharmaceuticals BMRN BRINEURA — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's brineura — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's BRINEURA — total revenues?
- BioMarin Pharmaceuticals (BMRN) reported BRINEURA — total revenues of $47.1M in Q1 2026.
- How has BioMarin Pharmaceuticals's BRINEURA — total revenues changed year-over-year?
- BioMarin Pharmaceuticals's BRINEURA — total revenues increased by 16.7% year-over-year, from $40.36M to $47.1M.
- What is the long-term trend for BioMarin Pharmaceuticals's BRINEURA — total revenues?
- Over 4 years (2021 to 2025), BioMarin Pharmaceuticals's BRINEURA — total revenues has grown at a 9.8% compound annual growth rate (CAGR), from $128.03M to $186.4M.
- What does BRINEURA — total revenues mean?
- The total sales revenue generated by a specific therapeutic product.
- How do you interpret BRINEURA — total revenues?
- An increase indicates growing market adoption or successful expansion of the patient base, while a decrease may signal increased competition, patent expiration, or market saturation.
- How does BRINEURA — total revenues compare across companies?
- Comparable to product-specific net sales reported by other specialty pharmaceutical and biotechnology companies.